Navigation Links
Microbix Biosystems Provides a Corporate Update
Date:10/29/2009

certainties that could cause actual results to differ materially from those set forth in the forward-looking statements including the risks associated with failure to get regulatory approval, and release, of Kinlytic (TM)for distribution; inability to close financing for the Microbix-Hunan project; risks associated with commercializing the technologies including sales may not reach sales targets or be made at all, there is no guarantee that the Company will complete development of any technology and if it does that it will perform to commercially exploitable levels, other technologies may emerge before any technology developed by the Company enters the market, royalty rates may not be achievable, markets may not sustain demand for any product should world economies shift significantly, market utilization rates may not be reached, market value of products may vary, product launch dates and market utilization timetables may not be met; risks associated with the ability to license VIRUSMAX to industry; risks associated with failure to develop and commercialize SST; non-adoption of SST; competition in Microbix' core business; general economic conditions; intellectual property risks including challenges to protecting the Company's intellectual property rights, patents may not provide adequate protection of the Company's intellectual property, may not be successfully prosecuted and may be subject to challenge and risks of infringement of third party rights; risks of operating in foreign jurisdictions, including operating in China with its evolving legal and economic infrastructure and the involvement of the Chinese government departments at national, state and local levels in business and economic matters; creating risks associated with various levels of political and economic conditions and other risks including but not limited to, currency exchange rates and restrictions on foreign exchange; high rates of inflation; renegotiation or nullification of existing licenses, p
'/>"/>
SOURCE Microbix Biosystems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
2. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
3. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
4. Microbix Announces A New Technology Platform For The SST Project
5. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
6. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
7. Microbix Sales Grow 22% For Nine Months
8. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
9. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
10. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
11. Primera Biosystems Raises $21 Million in Series B Private Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Immune Pharmaceuticals Inc., or "Immune" ... Directors has elected Rene-Pierre Azria as a ... Committee, with oversight on strategic and financial transactions. Mr. ... Committee, the Compensation Committee and the Corporate Governance and ... commented: "I have a long-time interest in Life Sciences ...
(Date:4/21/2015)... , April 21, 2015  Novogen Limited (ASX:NRT; ... biotechnology company, advises that it has entered into ... fully-paid ordinary shares plus one attaching 6-month option ... every ordinary share issued, to institutional investors in ... a private placement for aggregate gross proceeds of ...
(Date:4/21/2015)... April 21, 2015 Leading-edge ... clinical applications will be presented at the ... scientists, regulators and clinicians from academia, industry ... sponsored by Invibio Biomaterial Solutions. The world-leading ... specialist in manufacturing and R&D for medical-device ...
(Date:4/20/2015)... April 20, 2015 Stent retriever thrombectomy, ... vessels in the brain reduced disability after stroke, ... Jovin, MD, President of the Society of Vascular ... is a giant step forward that will change ... stroke patients," said Jovin, who is associate professor ...
Breaking Biology Technology:Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 62nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3
... CV Therapeutics,Inc. (Nasdaq: CVTX ) today announced ... results for 2007 after the market closes on Tuesday,February ... at,5:00 p.m. EST, 2:00 p.m. PST, on the company,s ... on to the Company,s website at, http://www.cvt.com and ...
... In a letter to,Governor Jennifer Granholm today, ... Governor,s State of the State Address,wherein she called ... is the,statewide association for Michigan,s life sciences industry., ... the legislature, to diversify,the state,s economy by focusing ...
... Md., Jan. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... commercializing novel anti-infective products, today,announced that it has ... and warrants, resulting in the receipt of $21 ... use the proceeds from the financing to support,the ...
Cached Biology Technology:CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008 2MichBio Responds to Governor's Plan to Repeal Tort Reform Laws 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 2MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... that acts as a "master switch" in certain white ... The study, published in the journal Nature Immunology ... diseases such as rheumatoid arthritis that involve excessive inflammation. ... body uses against harmful stimuli such as infections or ...
... WASHINGTON, Jan. 15, 2011 In research described as "a ... reporting that cigarette smoke begins to cause genetic damage within ... Their report, the first human study to detail the ... cancer, appears in Chemical Research in Toxicology , one ...
... 2010) The kidney is made up of roughly 1 ... waste products from the blood, recycle some substances to be ... segment of nephrons, called the distal nephron, helps set blood ... Today scientists at The University of Texas Health ...
Cached Biology News:Scientists find the 'master switch' for key immune cells in inflammatory diseases 2'A stark warning:' Smoking causes genetic damage within minutes after inhaling 2
...
...
...
... This antibody recognizes murine IRF7 ... with other related IRF proteins. ... murine IRF7 protein was confirmed ... the 293T cells transfected with ...
Biology Products: